🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,265 results for “Gan” Clear

  1. XELOX combined with Fruquintinib and Sintilimab

    The First People's Hospital of Lianyungang

    Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. YPEG-rhEPO

    The First People's Hospital of Lianyungang

    Renal Anemia of Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  3. Yigansan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tourette Disorder

    phase 2 small molecule completed

    1 trial

  4. Yougui granules

    The First People's Hospital of Lianyungang

    Renal Insufficiency, Chronic

    phase 2 small molecule terminated

    1 trial

  5. Zanubrutinib

    The First People's Hospital of Lianyungang

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  6. Zanubrutinib

    The First People's Hospital of Lianyungang

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  7. Zanubrutinib+Rituximab+Lenalidomide

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. Zoladex

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  9. Zopiclone

    The First People's Hospital of Lianyungang

    Insomnia Chronic

    phase 2 small molecule completed

    1 trial

  10. [11C]CPPC PET ligand

    United Therapeutics Europe Ltd

    ALS

    phase 2 small molecule active

    1 trial

  11. anlotinib +TQB2450 + Oxaliplatin+S-1

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. anlotinib combined with penpulimab

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. anlotinib+TQB2450+nab-paclitaxel+cisplatin

    The First People's Hospital of Lianyungang

    Advanced Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  14. anti-CD7 CAR-pNK cells

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  15. anti-FLT3 CAR-T

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  16. anti-MUC1 CAR-pNK cells

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  17. autologous anti-BCMA chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    ITP

    phase 2 mab active

    1 trial

  18. bexarotene

    LIGAND PHARMACEUTICALS INC

    Cutaneous T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  19. bexarotene

    LIGAND PHARMACEUTICALS INC

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  20. botulinum toxin Type A

    Allergan Pharmaceuticals International Limited

    Benign Prostatic Hyperplasia

    phase 2 mab completed

    1 trial

  21. botulinum toxin type A

    Allergan Pharmaceuticals International Limited

    Cervical Dystonia

    phase 2 mab completed

    1 trial

  22. cadonilizumab combined with neoadjuvant radiochemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 other active

    1 trial

  23. cardonilizumab combined with renvastinib

    The First People's Hospital of Lianyungang

    Resectable Clear Cell Carcinoma of the Kidney

    phase 2 small molecule active

    1 trial

  24. chidamide + camrelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources